VIVUS
Specialty pharma -- wholly-owned subsidiary of Icahn Enterprises (via IEH Biopharma LLC) since its Chapter 11 emergence; formerly NASDAQ-listed as VVUS
Privately held: no public share price · United States
Assets
(2 total)
2Total Assets
1Approved
1Phase 3 / Filed
0Phase 1–2 / Early
2Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
phentermine/topiramate(Qsymia) | Approved | Noradrenergic/anticonvulsant (combination)Small molecule | Obesity |
| Phase 3 | CalcineurinSmall molecule | Pulmonary Arterial Hypertension |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2028 (1)
May 2028 (1)
Extended-release tacrolimus (VI-0106)Phase 3Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH) …
Est. primary completion 2028-05-31 · NCT07612657 · CT.gov ↗
What to watch
Financial reports
No financial reports recorded.